ONXX receives positive recommendation from ODAC. POZN bio-equivalence of PA32540 not shown. CYTK offering. CTIC President resigns

Jun 21, 2012 No Comments by

Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced that the FDA Oncologic Drugs Advisory Committee (ODAC) voted 11-0 [with 1 abstention] in favour of  Kyprolis (carfilzomib) for the treatment of relapsed and refractory multiple myeloma. The PDUFA date  for accelerated approval is July 27, 2012.

Cytokinetics, Incorporated (Nasdaq: CYTK) priced two underwritten offerings for total gross proceeds of $60m.

Cell Therapeutics, Inc. (NASDAQ:CTIC) – Craig W. Philips delivered notice of his intention to resign as President of Cell Therapeutics, Inc., effective July 16, 2012.

POZEN Inc. (NASDAQ: POZN)  announced that the FDA, following analyses of a Phase 1 study (115 Study), does not agree that bioequivalence of PA32540 to EC aspirin 325 mg was demonstrated. POZEN has a planned follow-up call with the FDA in the next few weeks to determine next steps in satisfying the bioequivalence requirements and any impact on the New Drug Application (NDA) filing timeline.

 

 

Daily News

About the author

Currently residing in New Zealand and employed in the education industry, Mr. A. Burden holds a M.Com in International Business from the University of Sydney and used these skills together with his passion for investing to establish BioPharmCatalyst in June 2010 as a tool for investing decisions in the US pharmaceutical market. He spends much of his free time mountain biking, playing squash and hiking.
No Responses to “ONXX receives positive recommendation from ODAC. POZN bio-equivalence of PA32540 not shown. CYTK offering. CTIC President resigns”

Leave a Reply